Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Nomination Committee appointed for KlaraBo’s Annual General Meeting 2024

In accordance with the instruction to the Nomination Committee resolved by the Annual General Meeting 2021, The Nomination Committee shall include members selected by each of the three largest shareholders in terms of voting rights as of the last banking day in September 2023 and that wish to participate in the committee. The Nomination Committee has the following composition: · Roland Schylit appointed by Anders Pettersson with companies; · Kent Söderström, appointed by Investment AB Spiltan; · Mats Johansson appointed by own account. The main task of the Nomination

SENS expands its portfolio with a new battery and solar power project of 65 MW. The total portfolio today exceeds 400 MW of solar and battery parks.

Sustainable Energy Solutions Sweden Holding AB ("SENS") takes another step forward in its commitment to green energy transition by signing a new land lease agreement for a new project. The agreement is intended for the construction of a combined solar park and battery facility outside Katrineholm, Sörmland. The battery plant has a target of achieving a capacity of 50 MW and solar park of 15 MW.SENS announces today that a new land lease agreement has been successfully signed near Katrineholm, Sörmland. This marks the second agreement within a short period in the region. The project, which

Securitas Capital Markets Day, March 7, 2024 – Save the date

Securitas is pleased to invite investors, analysts and financial media to our Capital Markets Day on Thursday March 7, 2024, at 14.00 CET to approximately 17.00. The event will provide a strategic and financial update.The event will take place at Securitas’ Headquarter in Stockholm and will also be web casted. A formal invitation including agenda and registration will follow closer to the event.  Further information:Investors: Carina Florén; IR Manager +46 73 719 21 01, carina.floren@securitas.com

ChromoGenics enters cooperation with Smartglass International

October 27, 2023 ChromoGenics and Smartglass International of Ireland have signed a letter of intent regarding manufacturing, marketing and distribution of the dynamic glass ConverLight® Dynamic. Smartglass is a highly respected supplier & integrator of switchable glass solutions serving the European and North American markets with a proven track record of 4000+ projects across 35 countries world-wide. Since 2001, Smartglass International and its specialist team have been providing customers an unparalleled experience and world-class quality, focusing on switchable glass. The company

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 180 - 27 OCTOBER 2023 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 112/23 and 113/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

iPoint chooses DecideAct's software for its strategy management

DecideAct has signed a contract with iPoint, a market-leading provider of compliance and sustainability software solutions for blue-chip customers in Europe and the US. iPoint will use DecideAct's digital platform to manage the company's own strategic initiatives and sustainability objectives.Since 2001, companies such as Becton Dickinson, Ford, GE, Magna, Logitech, and Toyota have used iPoint's software to manage product compliance and sustainability by digitizing product lifecycle and supply chain relationships. Using iPoint's software, companies can collect and analyze all necessary data

New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that its commercial partner Everest Medicines (HKEX 1952.HK) (“Everest”) received approval from the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China.  The approval for Nefecon is for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. Macau is the first region in Everest territories that received Nefecon approval.The NDA for Nefecon in mainland China is under Priority Review and Nefecon was the first non-

Invitation to presentation in conjunction with Acroud's third quarter of 2023

On Thursday 9[th] November at 08:00 a.m. CET Acroud's interim report for the third quarter of 2023 will be published. At 10:00 a.m. CET the same day, a presentation of Acroud's interim report for the third quarter of 2023 will be presented.CEO Robert Andersson and CFO Andrzej Mieszkowicz will present the report, followed by a Q&A session. The presentation will be held in English and will be webcasted live through www.acroud.com or via https://ir.financialhearings.com/acroud-q3-report-2023.   To join the conference via phone, please dial-in using any of the numbers below: From Sweden:

Interim Report Q3 January-September 2023

The third quarter: · Order intake was MSEK 2,026 (1,891), an increase of +7.1% adjusted to +0.8% for currency effects of MSEK +125 and business closures of MSEK -5 · Net sales were MSEK 2,079 (2,081), a decrease of -0.1% adjusted to -4.0% for currency effects of MSEK +128 and business closures of MSEK -47 · Operating profit was MSEK 239.6 (218.8), an increase of +9.5% with an operating margin of 11.5 (10.5)% · Earnings after tax were MSEK 158.9 (156.9) · Earnings per share were SEK 0.90 (0.89) · Cash flow from operating activities was MSEK 311.5 (85.3) Comment from

Arjo secures renewal of major rental tender in France

Arjo wins the highly esteemed UGAP rental tender in France, securing yet another five years of offering premium rental solutions to healthcare providers across France. The win is also another step in the company’s journey towards driving profitable growth and a proof of Arjo’s position as a trusted partner to healthcare.   The rental tender is organized by the French public procurement organization UGAP, and Arjo is the incumbent tender provider – a position held by the company over the last ten years. The renewed contract covers more than 900 customers, representing a total annual

Brits upskilling: nine in ten adults are learning a new skill shows research

  Latest research into learning, skills and interests reveals that almost nine in ten (85 percent) Brits consider themselves to be ‘lifelong learners’, with 77 percent having taken a continued education course and 46 percent of people reporting it to be in the last 3 years. The main reasons for wanting to learn something new are related to improving brain health, mental wellbeing and enjoyment but increasing income is also a factor why people are upskilling.   When learning a new skill, almost a third (27%) put aside more than 50 hours a month of their time to perfect it,

Nomination Committee for Scandi Standard for the annual general meeting 2024

The nomination committee for Scandi Standard AB’s (publ) annual general meeting 2024 consists of the following members:  · Anders Wennberg (chairman, appointed by Investment AB Öresund); · Avelino Gaspar (appointed by Lusiaves Group); · Michael Sigsfors (appointed by Lantmännen); · Mats Qviberg (appointed by Eva Qviberg); and · Johan Bygge (chairman of the board of directors of Scandi Standard). The nomination committee is to prepare and make proposals to the annual general meeting 2024 regarding: · elections of the chairman of the annual general meeting, the

Heliospectra (publ) Publish the Interim Report for January to September 2023

(GOTHENBURG, Sweden, Oct 27, 2023, at 08:40 CEST)– Heliospectra AB (publ), a leader in intelligent lighting technology for greenhouse and controlled plant growth environments, presents its Interim Report for January to September 2023.Full report is enclosed to this press release and is also uploaded at https://heliospectra.com/investor-relations/financial-reports-documents/reports/. SUMMARY OF REPORT Sales and financial performance July – September 2023 · Order intake during the period amounted to SEK 7,527 (9,262) thousand. · Net sales during the period amounted to SEK 8,276 (

Notice for extra general meeting of the shareholders in Katalysen Ventures AB (publ)

Katalysen Ventures AB ( publ ) (“Katalysen” or the “Company”) will hold an extraordinary general meeting on November 13, 2023 at 09:00 at the company's premises at Birger Jarlsgatan 22, Stockholm, Sweden.RIGHT TO PARTICIPATE AND REGISTRATION Shareholders who wish to participate in the extraordinary general meeting must be entered as a shareholder in the share register kept by Euroclear Sweden AB regarding the conditions 3 November 2023, notify their participation at the general meeting no later than 7 November 2023. Notification of participation takes place via email to ad@

CONVENING NOTICE - EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (PUBL)

LUND (SWEDEN) – Immunovia AB (publ), reg. no. 556730-4299 (the “Company”), hereby gives notice that an extraordinary general meeting will take place on Tuesday 21st November 2023 at 10.00 in the Company’s offices at Medicon Village, Scheeletorget 1, Lund. Registration to the extraordinary general meeting starts at 09:45.  Notice/Right to participate at the general meeting  A shareholder who wishes to participate in the extraordinary general meeting must (i) be recorded in the share register prepared by Euroclear Sweden AB relating to the circumstances on the 13th November 2023, and (

PostNord Interim Report Q3 2023 – Adjustments to operations continuing

Third quarter 2023 · Net sales totaled SEK 9,149 million (9,456),a decrease of -6 percent (-2) in fixed currency for like-for-like units · Parcel volumes decreased by in all -2 percent (-4) · Mail volumes decreased by -16 percent (-11) · Operating income (EBIT) totaled SEK -6 million (65) · Adjusted operating income (adjusted EBIT) was SEK -6 million (108)Comments from Annemarie Gardshol, CEO   Third quarter The Group’s sales totaled SEK 9,149 million (9,456), a decrease of -6 percent in fixed currency for like-for-like units. Operating income totaled SEK -6

Elite Prospects Becomes Official Career Partner of the 2024 IIHF World Junior Championship

Everysport Group's world-leading hockey platform, Elite Prospects, becomes official career partner of the 2024 IIHF World Junior Championship to be played in Gothenburg this Christmas/New Year. The partnership underscores Elite Prospects' strong commitment to hockey and its global community.Elite Prospects  already supports the development of international hockey in a variety of ways and now joins the list of national partners for the 2024 IIHF World Junior Championship. The tournament is a major event in hockey, and the level of interest amongst EP

Interim Report 1 January – 30 September 2023

· US: Commercial business started promising with the first surgeries performed. 510(k) application for Episealer® MTP-system submitted · OUS: Continued steady growth driven by continued strong growth in customer base · Execution of re-structuring program ongoing”In connection with the report for the third quarter of 2023, we clearly show we are on the right track. The expansion of the business model, both in terms of the product portfolio and geographies, is now showing clear progress, and we expect this development to continue at an increasingly rapid pace. While posting 86% revenue

MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2023

“Updated data show that the combination fostrox + Lenvima® provides improved clinical efficacy compared to Lenvima study data alone in second-line HCC”July – September Financial summary for the quarter · Net turnover amounted to SEK 0.8 (1.1) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -23.4 (-13.9) million. Basic and diluted earnings per share amounted to SEK -0.42 (-0.27) and SEK -0.42 (-0.27) respectively. · Cash flow from operating activities amounted to SEK -21.0 (-19.7) million. · Cash and cash equivalents at the

Genova contemplates to issue new green bonds and announces a voluntary tender offer under outstanding bond loan 2020/2024 prior to a contemplated early redemption of the bond loan

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS (IN PARTICULAR, THE UNITED STATES AND

Exercise of options

Faron Pharmaceuticals Ltd.   (“Faron”)   Exercise of options Issue of equity   Company announcement, October 27, 2023 at 7:15 a.m. BST / 9:15 a.m. EEST   TURKU, FINLAND / BOSTON, MA – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical- stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that it has received notifications from option holders to exercise 2015B options over 22,306 in the Company at an exercise price of EUR 2.90 (approx. GBP 2.48) per share and 2015D options over 25,873 shares in the

Terveystalo's financial reporting and Annual General Meeting in 2024

Terveystalo Plc, Stock Exchange Release, Financial Calendar, 27 October 2023 at 09:05 EEST In 2024, Terveystalo will publish financial information as follows: Financial statements release 2023                                         14 February 2024Annual Report 2023                                                                Week 8Interim Report, 1 January 1 – 31 March 2024                        26 April 2024Half-yearly Report, 1 January – 30 June 2024                       17 July 2024Interim Report, 1 January – 30 September 2024                   25 October 2024 The

The Nomination Committee’s proposal for the election of the Board of Directors of AcadeMedia AB (publ)

The Nomination Committee of AcadeMedia presents the following proposal for a decision at the Annual General Meeting on November 30, 2023, regarding the number of Board members and the election of members and Chairman of the Board. The Nomination Committee proposes seven members elected by the Annual General Meeting, without deputy members. The Nomination Committee proposes re-election of Board members Johan Andersson, Ann-Marie Begler, Jan Bernhardsson, Mikael Helmerson and Håkan Sörman. The Board members Pia Rudengren and Silvija Seres have announced that they decline re-election.

There are no items matching the current filter
There are no more items matching the current filter
Back to top